GlobeImmune proposes IPO

GlobeImmune Inc. (Louisville, Colo.) proposed to raise up to $69 million in an IPO underwritten by Wells Fargo; Piper Jaffray; and JMP Securities. GlobeImmune's portfolio includes two products in Phase IIb testing: GI-4000 for pancreatic cancer and GI-5005 for HCV. GI-5005 is a whole heat-killed recombinant Saccharomyces cerevisiae yeast engineered to express a fusion protein of HCV non-structural protein 3 (NS3) and HCV core protein. GI-4000 is a whole heat-killed recombinant Saccharomyces cerevisiae genetically modified (Tarmogen) that activates the immune system against cancer cells with a mutated Ras protein. Celgene Corp. (NASDAQ:CELG) has an option to license exclusive, worldwide rights the compound. ...